Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene AXL
Variant over exp
Impact List none
Protein Effect no effect
Gene Variant Descriptions AXL over exp indicates an over expression of the Axl protein. However, the mechanism causing the over expression is unspecified.
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL over exp melanoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment inhibited viability of a BRAF wild-type melanoma cell line overexpressing Axl in culture (PMID: 35332208). 35332208
AXL over exp prostate cancer sensitive Bemcentinib + Metformin Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp head and neck squamous cell carcinoma sensitive Cetuximab + Imatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gleevec (imatinib) treatment in combination with Erbitux (cetuximab) synergistically inhibited tumor growth and induced regression in an Erbitux (cetuximab)-resistant cell line xenograft model of head and neck squamous cell carcinoma overexpressing AXL (PMID: 32439698). 32439698
AXL over exp triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). 27923843
AXL over exp prostate cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment did not decrease proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture, and did not inhibit tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL over exp head and neck cancer sensitive Bemcentinib + Erlotinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012). 24026012
AXL over exp head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment in combination with Erbitux (cetuximab) synergistically inhibited proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture (PMID: 32439698). 32439698
AXL over exp lung non-small cell carcinoma predicted - sensitive SGI-7079 Preclinical - Cell line xenograft Actionable In a preclinical study, SGI-7079 inhibited growth of mesenchymal non-small cell lung cancer cell lines expressing high levels of AXL in culture and reduced tumor growth in xenograft models (PMID: 23091115). 23091115
AXL over exp Advanced Solid Tumor sensitive RXDX-106 Preclinical - Cell line xenograft Actionable In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells over expressing Axl in culture, resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...
EML4 - ALK AXL over exp lung non-small cell carcinoma resistant Alectinib Preclinical - Cell line xenograft Actionable In a preclinical study, Alecensa (alectinib) failed to inhibit cell growth, phosphorylation of Alk and Axl, or downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 33627640). 33627640
EML4 - ALK AXL over exp lung adenocarcinoma no benefit Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL did not demonstrate sensitivity to Bemcentinib (BGB-324) treatment in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung adenocarcinoma predicted - sensitive Bemcentinib + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) and Xalkori (crizotinib) combination treatment did not induce apoptosis, however, inhibited proliferation of Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung non-small cell carcinoma sensitive Gilteritinib Preclinical - Cell line xenograft Actionable In a preclinical study, Xospata (gilteritinib) inhibited cell growth, phosphorylation of Alk and Axl, and downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture and suppressed tumor growth in cell line xenograft models and inhibited tumor growth when administered to separate xenograft models that had previously demonstrated resistance to Alecensa (alectinib) treatment (PMID: 33627640). 33627640
AXL over exp BRAF V600E melanoma sensitive Bemcentinib + Vemurafenib Preclinical - Cell line xenograft Actionable In a preclinical study, Bemcentinib (BGB-324) and Zelboraf (vemurafenib) combination treatment synergistically inhibited viability of melanoma cell lines harboring BRAF V600E and overexpressing Axl in culture, and resulted in improved tumor growth inhibition and tumor regression over either agent alone in a cell line xenograft model (PMID: 35332208). 35332208
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References